SUPPLEMENTAL EXPERIMENTAL PROCEDURES

CD1d functional experiments
CD1d internalization
Negatively purified B cells were stimulated with 10ng/ml PMA (Sigma-Aldrich) for 1 hour at 37°C. Cells were membrane stained with purified CD1d mAb for 30 min on ice and incubated with an AF488-conjugated goat anti-mouse IgG2b for 30 min on ice. Cells were incubated in complete medium in the presence or absence of anti-Ig (SouthernBiotech) and/or recombinant human IFNα (ImmunoTools) at 37°C for the indicated time-points, fixed with 2% PFA and mounted for confocal microscopy on glass slides with antifade reagent containing DAPI (Invitrogen). Images were obtained on a Leica DMIRE2 microscope with a 63x objective.
Alternatively, CD1d recycling was analyzed by flow cytometry using CD1d-PE mAb. Where indicated, cells were acid washed (PBS pH2) for removal of surface antibodies. The percentage internalization was calculated by MFI acid washed cells/MFI PBS washed cells x100.
CD1d recycling
CD1d recycling was assayed as previously described (Yuan et al., 2006) . Negatively purified B cells were incubated with saturating amounts of purified CD1d mAb on ice for 30 min. After washing, cells were incubated at 37°C for 20 min and placed on ice. Recycling of unblocked CD1d to the cell-surface was detected by flow cytometry with CD1d-PE mAb. CD1d recycling was measured as an increase in CD1d MFI compared to cells that were left on ice.
Quantitative immunoblots
B cell lysates from SLE patients as well as healthy donors were run on a 10% SDS-PAGE, immunoblotted with CD1d or Actin mAbs and detected by chemiluminescence. Adobe Photoshop was used for quantification (Adobe Systems Incorporated, USA). SLE patients fulfilling the revised classification criteria for SLE (Tan et al., 1982) were assessed for disease activity with the British Isles Lupus Assessment Group index (BILAG). The BILAG activity index distinguishes activity in 9 organs/systems (Rahman and Isenberg, 2008) . Patients with active SLE disease (BILAG global score >6) were compared to patients without active disease (BILAG global score <6). All SLE patients treated with rituximab had active disease prior to rituximab treatment. Patients were considered to be B cell depleted (BCD) when the level of B cells in peripheral blood was below 5 cells/µl, at this point their disease became inactive (BILAG <6) in most cases. Responding patients (RBRr) remained in remission with inactive disease after B cell repopulation; nonresponding patients (RBRnr) developed active disease (BILAG >6) concomitant to B cell repopulation. The clinical response of rituximab-treated patients was determined upon B cell repopulation, a phenomenon that varies from 3 months to 11 years between patients (Leandro et al., 2005) . No patients in the study were treated with intravenous immunoglobulin (IVIG). Age and sex-matched healthy controls were studied in parallel as well as age-matched Rheumatoid Arthritis and Sjögren's syndrome patients as other autoimmune disease (OAD) controls. Patients and controls were recruited after providing informed consent.The following abbreviations were used: Caucasian (C), Asian (A), African Carribbean (AC), Other (O), prednisolone (pred) and hydroxychloroquine (hcq), not determined (ND), systemic lupus erythematosus (SLE), B cell depleted (BCD), rituximab B cell repopulated non-responding (RBRnr), rituximab B cell repopulated responding (RBRr).
